- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00384579
Pilot Study to Assess the Efficacy of Botulinum Toxin B on Pain and Disability in Subjects With Acute Low Back Pain
1. marts 2010 opdateret af: United States Department of Defense
Pilot Study to Assess the Efficacy of Botulinum Toxin B (Myobloc®) Treatment of Paravertebral Muscles on Pain and Disability in Subjects Suffering From Acute Low Back Pain
This study will test the hypothesis that Botulinum toxin B (Myobloc®) treatment reduces pain and disability in subjects suffering from acute low back pain due to an identifiable muscle strain or back trauma occurring 3 to 6 weeks prior to enrollment.
The study will also delineate the duration of medication effect and control for any placebo or mechanical trigger-point injection effect by employing a prospective, double-blind, placebo-controlled design.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study will assess the efficacy of Botulinum Toxin B (Myobloc®) injected into the lumbar paravertebral muscles for reducing pain and disability in subjects suffering from acute low back pain (duration 3 to 6 weeks) arising from an identifiable muscle strain injury or back trauma.
The treatment modality and techniques used are based upon three successful prior open-labeled pilot studies done by this research group investigating the effect of Botulinum Toxin A (BOTOX®) on relief of chronic low back pain.
This study, however, will employ a prospective, double-blind, randomized, placebo controlled trial to control for any placebo or mechanical trigger-point injection effects.
Subjects will also be assessed for 3 months to define the duration of efficacy of Myobloc®.
Sixty subjects will be randomly assigned to one of two groups and will then receive either Myobloc® or placebo injection into the lumbar paravertebral muscles.
The subjects will be assessed using validated scales for pain and disability prior to injection and weekly to monthly thereafter for three months.
All subjects will continue to receive any medication or physiotherapy per standard of care but those treatments will be recorded and controlled for in the data analysis.
Undersøgelsestype
Interventionel
Fase
- Fase 4
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
District of Columbia
-
Washington, District of Columbia, Forenede Stater, 20307
- Walter Reed Army Medical Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 60 år (Voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Male or female subjects, 18 to 60 years of age, active duty military, retired military or other DOD beneficiaries eligible for care at military treatment facilities.
- Written informed consent and written authorization for use or release of health and research study information.
- Clear history of an identifiable muscle strain or trauma preceding the onset of low back pain.
- No prior history of vertebral disk disease/condition, sciatica or radiculopathy.
- Normal neurological examination without evidence of radiculopathy.
- Evidence of trigger point tenderness or muscle spasm upon palpation or EMG findings of muscle spasm.
- History of low back pain lasting 3 to 6 weeks from the time of injury or strain.
- VAS score minimum of 5 cm at time of entry into study.
- Ability to follow study instructions and likely to complete all required visits.
- Negative urine pregnancy test prior to the administration of study medication (for females of childbearing potential) (if applicable).
Exclusion Criteria:
- Age less than 18 or greater than 60.
- Not active duty.
- Concomitant use of aminoglycoside antibiotics, curare-like agents, or other agents that might interfere with neuromuscular function.
- Any medical condition that may put the subject at increased risk with exposure to Myobloc®, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis/motor neuron disease, neuropathy, renal stones, or any other disorder that might interfere with neuromuscular function or produce a similar type of low back pain.
- Females who are pregnant, breast-feeding, or planning a pregnancy during the study, or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.
- Known allergy or sensitivity to any of the components in the study medication.
- Evidence of alcohol or substance abuse in 6 months prior to enrollment.
- Systemic medical conditions (such as thyroid disease, hypertension, bleeding disorders, diabetes, cancers, etc.) that are not currently medically managed or controlled.
- Concurrent participation in another investigational drug or device study or participation in the 30 days immediately prior to study enrollment.
- Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.
- Significant Axis I or II diagnosis determined by a neurologist or psychiatrist in the 6 months prior to entry into the study.
- Duration of low back pain < 3 weeks or > 6 weeks.
- Thoracic or cervical spine pain in the absence of acute low back pain.
- Anesthetic or corticosteroid injection to the lumbosacral spine within 8 weeks of enrollment.
- Spine MRI (any region) positive for acute pathology or evidence of radiculopathy on neurological examination.
- History of back surgery within one year or incomplete resolution of back pain due to a previous injury or surgery.
- Subjects involved in litigation, seeking significant disability for low back pain, or with evident secondary gain as determined by the neurologist through chart review and subject interview.
- Any previous use of Myobloc®, Dysport®, or BOTOX®.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Placebo komparator: 2
Placebo
|
Placebo
|
Eksperimentel: 1
Botulinum Toxin B
|
Botulinum Toxin B
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Significant improvement in lower back pain
Tidsramme: 8 weeks
|
8 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Significant reduction of long term disability
Tidsramme: 12 weeks
|
12 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Wipf JE, Deyo RA. Low back pain. Med Clin North Am. 1995 Mar;79(2):231-46. doi: 10.1016/s0025-7125(16)30065-7.
- Frymoyer JW. Predicting disability from low back pain. Clin Orthop Relat Res. 1992 Jun;(279):101-9.
- Rand MJ, Whaler BC. Impairment of sympathetic transmission by botulinum toxin. Nature. 1965 May 8;206(984):588-91. doi: 10.1038/206588a0. No abstract available.
- Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001 May 22;56(10):1290-3. doi: 10.1212/wnl.56.10.1290.
- Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005 Oct;26(5):785-93. doi: 10.1016/j.neuro.2005.01.017. Epub 2005 Jul 5.
- Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000;55(12 Suppl 5):S29-35.
- Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001 Apr;248 Suppl 1:3-10. doi: 10.1007/pl00007816.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. februar 2008
Primær færdiggørelse (Forventet)
1. august 2010
Studieafslutning (Forventet)
1. august 2010
Datoer for studieregistrering
Først indsendt
4. oktober 2006
Først indsendt, der opfyldte QC-kriterier
5. oktober 2006
Først opslået (Skøn)
6. oktober 2006
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
2. marts 2010
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
1. marts 2010
Sidst verificeret
1. februar 2010
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- DCI P05-71031
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Lændesmerter
-
Bozok UniversityAfsluttet
-
Otsuka Pharmaceutical Co., Ltd.Aktiv, ikke rekrutterendeHyper-low-density Lipoprotein (LDL) KolesterolæmiJapan
-
Health Services Academy, Islamabad, PakistanUkendtmHealth | Genoptagelse | Teach-back kommunikationPakistan
-
Rush University Medical CenterAfsluttetPatientuddannelse | Teach-back kommunikation | Efter besøgsinstruktioner | PatientforståelseForenede Stater
-
InQpharm GroupAfsluttetBlodtryk | Low Density Lipoprotein KolesterolniveauTyskland
-
Otsuka Pharmaceutical Co., Ltd.AfsluttetHyper-low-density Lipoprotein (LDL) KolesterolæmiJapan
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinAktiv, ikke rekrutterendeSimulering af fysisk sygdom | Trakeostomi komplikation | Teach-back kommunikationForenede Stater
-
Marmara UniversityAktiv, ikke rekrutterendeTeach-back kommunikationKalkun
-
National Taiwan University HospitalBuddhist Tzu Chi General Hospital; Taipei Medical University Hospital; E-DA... og andre samarbejdspartnereUkendtKoloskopi | Udrensning af tyktarm | Low-Reside diætTaiwan
-
Jordan Collaborating Cardiology GroupThe Cardiovascular Academy Group of the JCS; The Jordan Cardiac Society... og andre samarbejdspartnereAfsluttetAterosklerotisk kardiovaskulær risiko | Low-density-lipoprotein (LDL) kolesterolJordan
Kliniske forsøg med Placebo
-
SamA Pharmaceutical Co., LtdUkendtAkut bronkitis | Akut øvre luftvejsinfektionKorea, Republikken
-
National Institute on Drug Abuse (NIDA)AfsluttetBrug af cannabisForenede Stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAfsluttetMandlige forsøgspersoner med type II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAfsluttetFarmakokinetik | SikkerhedsproblemerDet Forenede Kongerige
-
Regado Biosciences, Inc.AfsluttetSund frivilligForenede Stater
-
Texas A&M UniversityNutraboltAfsluttetGlucose and Insulin Response
-
Longeveron Inc.AfsluttetHypoplastisk venstre hjerte syndromForenede Stater
-
ItalfarmacoAfsluttetBeckers muskeldystrofiHolland, Italien
-
Universidade Estadual de LondrinaConselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination...AfsluttetSund og rask | Kropssammensætning